A multi-center, randomized, double-blind, active-controlled clinical trial to evaluate the safety and tolerability of 24 weeks treatment with Vildagliptin (50 mg) versus Sitagliptin (25 mg) in patients with type 2 diabetes and severe renal insufficiency